Form 8-K - Current report:
SEC Accession No. 0001628280-25-036445
Filing Date
2025-07-29
Accepted
2025-07-29 16:54:29
Documents
13
Period of Report
2025-07-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cdxc-20250725.htm   iXBRL 8-K 27798
2 EX-10.1 ex101-salesagreementdatedj.htm EX-10.1 108262
  Complete submission text file 0001628280-25-036445.txt   275332

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdxc-20250725.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdxc-20250725_lab.xml EX-101.LAB 21689
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdxc-20250725_pre.xml EX-101.PRE 12519
15 EXTRACTED XBRL INSTANCE DOCUMENT cdxc-20250725_htm.xml XML 2735
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Filer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37752 | Film No.: 251162498
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)